Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNP-201 in Peanut Allergy
NCT04950504Phase 1Terminated
- Sponsor
- COUR Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CNP-201 in peanut allergy (4 arms), sponsored by COUR Pharmaceuticals. Primary endpoints: Frequency of Adverse Events and Serious Adverse Events at 90 Days, Serum Cytokines (TNF-α, IL-2, IL-6, IL-8, IL-1β, MCP-1, MIP-1β, MIP-1α, IFN-γ, and IL-12p70) at 90 Days and 2 more. Started Jun 2021; status: terminated.
02
Drugs
CNP-201
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT04950504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950504.